Our Canadian data holdings contain nearly 100% of all pharmaceutical products sold and shipped in Canada, and more than 70% of all prescriptions dispensed in community pharmacies. This data is rich and complex, allowing organizations to monitor chronic disease progression, incidence, prevalence, and growth at very detailed levels.
Expertise and assets can be leveraged from our international colleagues (across 100 countries), including established relationships with other major top performing health systems (groups like the FDA, NHS, German Health Ministry and the UAE). Our international data sources allows Canadians to benchmark and compare.
Successful applications of our AI/ML algorithms to both our data and third-party data sets include looking at historical patterns and disease progressions that predict the pathway of a patient. This knowledge allows data scientists to look for similar patients earlier in their disease journey with the goal of supporting providers with early intervention and monitoring strategies.
IQVIA’s OneKey data holds the most current locations, counts, and specialties of physicians in Canada, ensuring your agency always has the most accurate and maintained physician contact information. Our integrated data solutions can provide additional insights like estimated roster sizes and disease/practice profiles.
IQVIA’s longitudinal dispensing data (LRx) allows stakeholders to examine the percentage of patients who are dispensed a chronic medication that do or do not demonstrate 100% compliance. We can deliver insights as to how physician groups compare, allowing you to identify and assist specific populations and stakeholders, including how to work with large pharmaceutical companies to bolster patient education and support programs.
IQVIA employs our prescription data, advanced algorithms, and data science techniques to assist healthcare providers in determining what is happening in their community and how it is shifting in near real time. Through working with data science and clinical experts, IQVIA has aligned pharmaceutical trends to disease identification, disease acuity, and disease progress.